KR20220049023A - 뎅기열 및 a형 간염을 예방하기 위한 방법 - Google Patents
뎅기열 및 a형 간염을 예방하기 위한 방법 Download PDFInfo
- Publication number
- KR20220049023A KR20220049023A KR1020227008716A KR20227008716A KR20220049023A KR 20220049023 A KR20220049023 A KR 20220049023A KR 1020227008716 A KR1020227008716 A KR 1020227008716A KR 20227008716 A KR20227008716 A KR 20227008716A KR 20220049023 A KR20220049023 A KR 20220049023A
- Authority
- KR
- South Korea
- Prior art keywords
- dengue
- hepatitis
- vaccine
- serotype
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
- C12N2770/32434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IDP00201907241 | 2019-08-16 | ||
| IDPID2019-07241 | 2019-08-16 | ||
| EP19195692.9 | 2019-09-05 | ||
| USPCT/US2019/049749 | 2019-09-05 | ||
| US16/561,953 US11590221B2 (en) | 2018-09-05 | 2019-09-05 | Dengue vaccine unit dose and administration thereof |
| EP19195692.9A EP3620174B1 (en) | 2018-09-05 | 2019-09-05 | Dengue vaccine unit dose and administration thereof |
| PCT/US2019/049749 WO2020051334A1 (en) | 2018-09-05 | 2019-09-05 | Dengue vaccine unit dose and administration thereof |
| US16/561,953 | 2019-09-05 | ||
| PCT/US2020/020991 WO2021034349A1 (en) | 2019-08-16 | 2020-03-04 | Methods for preventing dengue and hepatitis a |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20220049023A true KR20220049023A (ko) | 2022-04-20 |
Family
ID=74660757
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020227008716A Pending KR20220049023A (ko) | 2019-08-16 | 2020-03-04 | 뎅기열 및 a형 간염을 예방하기 위한 방법 |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP4013451A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7731344B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220049023A (cg-RX-API-DMAC7.html) |
| CN (1) | CN114555113A (cg-RX-API-DMAC7.html) |
| AU (3) | AU2020331884B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022001476A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3147807A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022001742A (cg-RX-API-DMAC7.html) |
| PH (1) | PH12022550261A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021034349A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20260167703A1 (en) * | 2022-11-02 | 2026-06-18 | Takeda Vaccines, Inc. | A method for determining the infectivity of a virus |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2345614T3 (es) | 1997-02-28 | 2010-09-28 | Sanofi Pasteur Biologics Co. | Vacunas quimericas de flavivirus. |
| AU2003239932A1 (en) | 2002-05-31 | 2003-12-19 | Acambis, Inc. | Tetravalent dengue vaccines |
| WO2007021672A2 (en) | 2005-08-10 | 2007-02-22 | Acambis Inc. | Vaccination against dengue virus infection |
| FR2903605A1 (fr) | 2006-07-12 | 2008-01-18 | Sanofi Pasteur Sa | Methode d'immunisation contre les quatres serotypes de la dengue |
| DK2054428T3 (da) | 2006-08-15 | 2013-08-26 | Government Of The U S A As Repr By The Secretary Dept Of Health & Human Services The Nat Inst Of Hea | Udvikling af bestanddele til denque-virus-vaccine |
| FR2906724B1 (fr) | 2006-10-04 | 2009-03-20 | Sanofi Pasteur Sa | Methode d'immunisation contre les 4 serotypes de la dengue. |
| FR2909286B1 (fr) | 2006-12-01 | 2012-06-08 | Sanofi Pasteur | Methode d'immunisation contre les 4 serotypes de la dengue |
| EP2931310A4 (en) * | 2012-12-14 | 2016-05-25 | Takeda Vaccines Inc | COMPOSITIONS, METHODS OF ADMINISTRATION AND USES OF TRIVALENT FORMULATIONS AGAINST DENGUE VIRUS |
| TWI852899B (zh) * | 2014-09-02 | 2024-08-21 | 法商賽諾菲巴斯德公司 | 疫苗組合物 |
| EP3316905A1 (en) * | 2015-07-03 | 2018-05-09 | Sanofi Pasteur | Concomitant dengue and yellow fever vaccination |
| JP2019511533A (ja) * | 2016-04-13 | 2019-04-25 | タケダ ワクチン, インコーポレイテッドTakeda Vaccines, Inc. | 小児及び若年成人のデングウイルスに対するワクチンの組成物及び方法 |
| TWI766876B (zh) | 2016-08-03 | 2022-06-11 | 美商武田疫苗股份有限公司 | 用於與經改良之調配物一起穩定黃病毒的組成物及方法 |
-
2020
- 2020-03-04 WO PCT/US2020/020991 patent/WO2021034349A1/en not_active Ceased
- 2020-03-04 PH PH1/2022/550261A patent/PH12022550261A1/en unknown
- 2020-03-04 AU AU2020331884A patent/AU2020331884B2/en active Active
- 2020-03-04 EP EP20719243.6A patent/EP4013451A1/en active Pending
- 2020-03-04 MX MX2022001742A patent/MX2022001742A/es unknown
- 2020-03-04 KR KR1020227008716A patent/KR20220049023A/ko active Pending
- 2020-03-04 CN CN202080071928.2A patent/CN114555113A/zh active Pending
- 2020-03-04 JP JP2022509723A patent/JP7731344B2/ja active Active
- 2020-03-04 BR BR112022001476A patent/BR112022001476A2/pt unknown
- 2020-03-04 CA CA3147807A patent/CA3147807A1/en active Pending
-
2024
- 2024-10-09 JP JP2024177535A patent/JP2025032070A/ja active Pending
-
2025
- 2025-04-23 AU AU2025202876A patent/AU2025202876B2/en active Active
-
2026
- 2026-04-15 AU AU2026202847A patent/AU2026202847A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2026202847A1 (en) | 2026-05-07 |
| WO2021034349A1 (en) | 2021-02-25 |
| JP2022544613A (ja) | 2022-10-19 |
| JP2025032070A (ja) | 2025-03-11 |
| AU2020331884B2 (en) | 2025-01-23 |
| PH12022550261A1 (en) | 2023-06-26 |
| AU2025202876B2 (en) | 2026-01-29 |
| MX2022001742A (es) | 2022-04-07 |
| EP4013451A1 (en) | 2022-06-22 |
| CN114555113A (zh) | 2022-05-27 |
| BR112022001476A2 (pt) | 2023-10-03 |
| CA3147807A1 (en) | 2021-02-25 |
| AU2020331884A1 (en) | 2022-03-03 |
| AU2025202876A1 (en) | 2025-07-03 |
| JP7731344B2 (ja) | 2025-08-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2019335006B2 (en) | Dengue vaccine unit dose and administration thereof | |
| CN101238209B (zh) | 登革血清型2减毒株 | |
| KR101464649B1 (ko) | 약독화된 뎅기 혈청형 1 균주 | |
| KR20180137514A (ko) | 어린이 및 젊은 성인에서 뎅기 바이러스에 대한 백신접종 조성물 및 방법 | |
| AU2026202847A1 (en) | Methods For Preventing Dengue And Yellow Fever | |
| US12201683B2 (en) | Methods for preventing dengue and hepatitis a | |
| HK40082761A (en) | Dengue vaccine unit dose and administration thereof | |
| WO2025072259A9 (en) | Coadministration of tetravalent dengue vaccine with hpv vaccine | |
| HK40023196B (en) | Dengue vaccine unit dose and administration thereof | |
| HK40023196A (en) | Dengue vaccine unit dose and administration thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| D21 | Rejection of application intended |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| T11 | Administrative time limit extension requested |
Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |